UWCCC Molecular Tumor Board Registry

UWCCC Precision Medicine Molecular Tumor Board Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03023202

Enrollment

10000

Registered

2017-01-18

Start date

2016-03-30

Completion date

2029-03-01

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Neoplasms, Solid Neoplasm

Brief summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Interventions

OTHERPMMTB (Precision Medicine Molecular Tumor Board)

PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinically suspected or histologically confirmed solid or hematological malignancy * Undergoing genetic testing of tumor * Ability to understand written informed consent document * Willingness to sign written informed consent document

Exclusion criteria

* Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Design outcomes

Primary

Measure	Time frame	Description
Frequency of acceptance of molecular tumor board recommendations	Up to 5 years	How often the molecular tumor board's recommendations are accepted
Benefit from PMMTB recommended treatment	Up to 5 years	Whether patients benefit from PMMTB recommended treatment

Secondary

Measure	Time frame	Description
Correlation of mutations with protein overexpression	Up to 5 years	Correlate mutations identified in tumor tissue with protein overexpression
Correlations of mutations with circulating tumor DNA	Up to 5 years	Correlate mutations identified in tumor tissue with circulating tumor DNA
Correlations of mutations with spheroid culture investigations	Up to 5 years	Correlate mutations identified in tumor tissue with spheroid culture investigations

Countries

United States

Contacts

CONTACTCancer Connect

clinicaltrials@cancer.wisc.edu8006228922

PRINCIPAL_INVESTIGATORDustin Deming, MD

University of Wisconsin, Madison

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026